CA2463142A1 - Methods for preventing and treating bone loss with steroid compounds - Google Patents

Methods for preventing and treating bone loss with steroid compounds Download PDF

Info

Publication number
CA2463142A1
CA2463142A1 CA002463142A CA2463142A CA2463142A1 CA 2463142 A1 CA2463142 A1 CA 2463142A1 CA 002463142 A CA002463142 A CA 002463142A CA 2463142 A CA2463142 A CA 2463142A CA 2463142 A1 CA2463142 A1 CA 2463142A1
Authority
CA
Canada
Prior art keywords
exemestane
hydro
bone
woman
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002463142A
Other languages
English (en)
French (fr)
Inventor
Enrico Di Salle
Giorgio Massimini
Colin Lowery
Paul Edward Goss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2463142A1 publication Critical patent/CA2463142A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002463142A 2001-10-10 2002-09-30 Methods for preventing and treating bone loss with steroid compounds Abandoned CA2463142A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32820901P 2001-10-10 2001-10-10
US60/328,209 2001-10-10
PCT/EP2002/011123 WO2003032961A2 (en) 2001-10-10 2002-09-30 Methods for preventing and treating bone loss with steroid compounds

Publications (1)

Publication Number Publication Date
CA2463142A1 true CA2463142A1 (en) 2003-04-24

Family

ID=23279989

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002463142A Abandoned CA2463142A1 (en) 2001-10-10 2002-09-30 Methods for preventing and treating bone loss with steroid compounds

Country Status (12)

Country Link
EP (1) EP1435967A2 (ja)
JP (1) JP2005508958A (ja)
KR (1) KR20050032507A (ja)
CN (1) CN1713915A (ja)
BR (1) BR0213162A (ja)
CA (1) CA2463142A1 (ja)
IL (1) IL161162A0 (ja)
MX (1) MXPA04003405A (ja)
NZ (1) NZ532064A (ja)
PL (1) PL370080A1 (ja)
WO (1) WO2003032961A2 (ja)
ZA (1) ZA200402734B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
WO2005027916A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors
US7332482B2 (en) 2003-09-24 2008-02-19 Bioxell S.P.A. Method for treating benign prostatic hyperplasia
EP1937251A2 (en) * 2005-04-25 2008-07-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
KR101698238B1 (ko) 2010-06-10 2017-01-19 세라곤 파마슈티컬스, 인크. 에스트로겐 수용체 조정제 및 이의 용도
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
HRP20211836T1 (hr) 2013-09-24 2022-03-04 Fujifilm Corporation Novi spoj koji sadrži dušik ili njegova sol, ili njegov metalni kompleks
CA3008023A1 (en) 2015-12-30 2017-07-06 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8721384D0 (en) * 1987-09-11 1987-10-21 Erba Farmitalia 17-substituted andro-sta-1 4-dien-3-one derivatives
GB2294879A (en) * 1994-10-19 1996-05-15 Merck & Co Inc Cylcooxygenase-2 Inhibitors
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
ID28460A (id) * 1998-07-08 2001-05-24 Lipogenics Inc Komposisi dan metoda untuk perlakuan dan pencegahan penyakit tulang dengan menggunakan tocotrienol
BR0013272B1 (pt) * 1999-08-13 2013-10-15 Uso de um inibidor de aromatase esteroidal

Also Published As

Publication number Publication date
EP1435967A2 (en) 2004-07-14
MXPA04003405A (es) 2004-06-18
JP2005508958A (ja) 2005-04-07
IL161162A0 (en) 2004-08-31
NZ532064A (en) 2006-04-28
WO2003032961A2 (en) 2003-04-24
CN1713915A (zh) 2005-12-28
KR20050032507A (ko) 2005-04-07
ZA200402734B (en) 2005-01-13
BR0213162A (pt) 2004-09-14
PL370080A1 (en) 2005-05-16
WO2003032961A3 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
CA2768882C (en) Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CA2376158C (en) Use of selective estrogen receptor modulators in the manufacture of medicaments for treating and/or suppressing weight gain
CZ20022401A3 (cs) Farmaceutický prostředek a souprava pro snížení nebo eliminaci výskytu symptomů menopauzy
WO1990010462A1 (en) Combination therapy for treatment of estrogen sensitive diseases
ZA200601237B (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist
KR20090060306A (ko) 비타민 ｄ 화합물 및 추가 치료제, 및 그를 함유하는 조성물을 투여하는 것을 포함하는, 암을 치료하는 방법
ES2251374T3 (es) Utilizacion de una formulacion combinada a base de metabolitos de la vitamina d o compuestos analogos a la vitamina d y de un agente agonista parcial de estrogenos para el tratamiento de la osteoporosis.
CA2463142A1 (en) Methods for preventing and treating bone loss with steroid compounds
KR20010052818A (ko) 선택적인 에스트로겐 수용체 조절제 및 부갑상선 호르몬을포함하는 치료적 혼합물
ES2399328T3 (es) Uso de 2-metilen-19-nor-20(S)-1a,25-dihidroxivitamina D3 para la profilaxis de enfermedades óseas
KR20010052852A (ko) 근골격 허약을 치료하기 위한 선택적인 에스트로겐 수용체조절제 및 성장 호르몬 분비촉진제의 치료적 혼합물
AU2002333895A1 (en) Methods for preventing and treating bone loss with steroid compounds
US20100056483A1 (en) Methods and compositions for the treatment and prevention of bone loss
WO2010126093A1 (ja) エルデカルシトールを含有する前腕部骨折抑制剤
AU2011253842B2 (en) Medical Uses of a Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors
Matsumoto et al. Combined effects of lutenizing hormone-releasing hormone analogue with antiestrogen on rat mammary tumors
PL203438B1 (pl) Kompozycja farmaceutyczna zawieraj aca dehydroepiandrosteron, pochodn a trifenyloetylenu i farmaceutycznie dopuszczaln a zaróbk e, zestaw i zastosowanie dehydroepiandrosteronu
PL203439B1 (pl) Kompozycja farmaceutyczna zawieraj aca dehydroepiandrosteron, pochodn a indolu i farmaceutycznie dopuszczaln a zaróbk e, zestaw i zastosowanie dehydroepiandrosteronu
JP2002538122A (ja) 天然に存在しないｆｐ選択的アゴニストおよび骨吸収抑制化合物を用いる骨体積の増加方法
AU2008255169A1 (en) Medical Uses of a Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued